DNA
Ginkgo Bioworks Holdings
NYSE: DNA · HEALTHCARE · BIOTECHNOLOGY
$9.70
+14.66% today
Updated 2026-05-01
Market cap
$551.05M
P/E ratio
—
P/S ratio
3.24x
EPS (TTM)
$-5.64
Dividend yield
—
52W range
$5 – $18
Volume
1.2M
Ginkgo Bioworks Holdings (DNA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-44.66M | $-135.83M | $-253.82M | $-252.20M | $-295.50M | $-319.58M | $-171.06M |
| Capital expenditures | $22.22M | $57.82M | $56.52M | $52.27M | $40.80M | $62.54M | $7.67M |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $771000.00 | $476000.00 | $1.61B | $1.93B | $229.88M | $112.34M | $81.55M |
| Free cash flow | $-66.88M | $-193.65M | $-310.34M | $-304.47M | $-336.30M | $-382.13M | $-178.72M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | $1.51B | $981000.00 | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $1.21B | $-224.25M | — | — | — |